SecBot SecBot

ALKS

Alkermes plc.
Nasdaq· Pharmaceutical Preparations· CIK 0001520262 Biotech & Drug Discovery
$46.53 −0.50 (−1.06%)
Nov 16 4:00 PM ET · prev $47.03
Market cap
$7.9B
Mid cap
Consensus
Buy
74% Buy or better · 27 analysts
Median target
$60.00
+29% · range $38.00–83.00
1 year
+58.6%
from $29.33 · Nov 17
30 days
+8.3%
from $42.97
52-week range
$27.20–55.22
−16% from high · low Mar 18
Avg volume 20D
1.64M
shares / day
Short interest
19.65M
≈11.7% of shares · +3.1%
Days to cover
11.3
at average volume
Insider net
−$5.7M
0 buyers · 6 sellers · since May 20
New fund stakes
4
Q3 2026 13F · 1 exit
Filing reports
23
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $5.7M.

  • InstitutionsBULLISH

    Q3 2026: 44 added (4 new), 19 trimmed or exited. Largest new: Capital World Investors $19.2M, Qube Research & Technologies $15.2M.

  • AnalystsBULLISH

    20 of 27 rate it Buy or better. Median target $60.00 (+29%).

  • Short sellersSTEADY

    Short interest +3.1% to 19.65M shares. 11.3 days to cover, ≈11.7% of shares.

  • TrendUPTREND

    7% above its 50-day average.

Who's buying

13F· Q3 2026
4
new positions
1
exit
$48.7M
in new stakes · top 3 shown
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCTRIM1,509,029$61.1M
Invesco Ltd.DOUBLED1,465,540$59.4M
PUBLIC SECTOR PENSION INVESTMENT BOARDADD1,082,205$43.2M
Artisan Partners Limited PartnershipTRIM575,511$23.3M
MANUFACTURERS LIFE INSURANCE COMPANY, THEDOUBLED533,522$21.6M
Capital World InvestorsNEW472,839$19.2M
UBS Group AGADD463,121$18.8M
Qube Research & Technologies LtdNEW375,083$15.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

27 analysts
Buy 74% rate it Buy or better
Strong Buy6Buy14Hold6Sell1Strong Sell0
12-month targets · 19 analysts

Price is inside the target range. Median implies +29%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 4, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Nov 4, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Nov 4, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINNeutral
Sep 22, 2026RBC Capital
REITERATE
REITERATEOutperform
Sep 22, 2026Baird
MAINTAIN
MAINTAINOutperform
Sep 21, 2026Needham
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$5.7M
sold · 6 insiders
DateInsiderTypeValue
Nov 3, 2026
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
Nov 3, 2026
SELL$94.0K
Oct 8, 2026
Reed Joshua
SVP, Chief Financial Officer
Oct 8, 2026
EXERCISE9,164 sh
Oct 8, 2026
Reed Joshua
SVP, Chief Financial Officer
Oct 8, 2026
TAX W/H$163.2K
Oct 7, 2026
Whitaker Anne Clem
Director
Oct 7, 2026
AWARD17,998 sh
Oct 7, 2026
Whitaker Anne Clem
Director
Oct 7, 2026
AWARD7,239 sh
Oct 2, 2026
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
Oct 2, 2026
SELL$83.5K
Sep 3, 2026
Gaffin David Joseph
EVP, CLO, Alkermes, Inc.
Sep 3, 2026
SELL$97.7K
Sep 1, 2026
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Sep 1, 2026
EXERCISE$123.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

88 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
19,647,994
shares short
+3.1%
vs prior settlement
11.3
days to cover
≈11.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Alkermes settled a patent infringement lawsuit with Teva over LYBALVI (olanzapine/samidorphan). Teva will receive a…
8-K · Impact 4/10
Nov 4, 2026 SEC
Three institutional investors (Strs Ohio, Mackenzie Financial, Allspring Global Investments) increased their ALKS…
INST-CLUSTER · Impact 3/10
Nov 3, 2026 SEC
David Gaffin, an officer of Alkermes, filed a Form 144 notice of intent to sell 2,035 shares of common stock, with an…
144 · Impact 2/10
Nov 3, 2026 Insider
Gaffin David Joseph sold 2,035 shares
EVP, CLO, Alkermes, Inc. @ $46.17 ($94.0K)
Nov 3, 2026 Earnings result
ALKS Q3 2026 Earnings: EPS $0.09 (+225.0% vs est)
Oct 8, 2026 Insider
Reed Joshua acquired via exercise 9,164 shares
SVP, Chief Financial Officer
Oct 8, 2026 Insider
Reed Joshua surrendered for taxes 4,069 shares
SVP, Chief Financial Officer @ $40.11 ($163.2K)
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · TRIM
1,509,029 shares ($61.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent

SecBot reports

23 filings · 2 bullish · 2 bearish · 2 mixed · 17 neutral
All ALKS filing & press-release reports (23)